An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy

Study Summary

This is a multicenter, prospective, observational Phase 4 study in the United States. The study is designed to collect both medical history and prospective data on Duchenne muscular dystrophy (DMD) treatment outcomes in participants receiving delandistrogene moxeparvovec as part of clinical care, compared to participants with DMD receiving or prescribed to start chronic glucocorticoid treatment at baseline in routine clinical practice.

Conditions

Duchenne Muscular Dystrophy

Interventions / Drugs

Delandistrogene Moxeparvovec Standard of Care

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment500 participants

Primary Completion—

Lead SponsorSarepta Therapeutics, Inc.

Data Retrieved2026-04-11 02:55:56.327597+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.